Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
VXB-232
- Development stage
- Unknown
- Lead developer
- Sanofi
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Administration
- Intramuscular
01
Overview
VXB-232 is a monovalent protein subunit vaccine candidate designed to prevent infections caused by parainfluenza virus type 3 (PIV3). Developed by Vicebio (acquired by Sanofi in 2025), the vaccine utilizes the proprietary Molecular Clamp technology discovered at the University of Queensland. This platform stabilizes the viral fusion (F) glycoprotein in its highly immunogenic prefusion conformation, which is critical for inducing potent neutralizing antibodies. VXB-232 is currently in Phase 1 clinical development, where it is being evaluated both as a standalone monovalent component and as a comparator for the trivalent vaccine candidate VXB-251, which targets RSV, hMPV, and PIV3.
- Other names
- monovalent parainfluenza virus 3 vaccinemonovalent (PIV3) vaccine candidate
Beyond the preview
Go deeper on VXB-232.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on VXB-232.